Rani Bansal

Rani Bansal

Assistant Professor of Medicine

Overview

My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations.

Positions

Assistant Professor of Medicine in the School of Medicine

2022 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2023 School of Medicine

Education

M.D., Boston University, School of Medicine 2016

2016 Boston University, School of Medicine

Residency, Boston University, School of Medicine, INTERNAL MEDICINE 2016 - 2019

2019 Boston University, School of Medicine

Clinical Trials

SMX22-002: Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

ASCENT-05 for Triple Negative Breast Cancer with Residual Disease after Surgery

pionERA Breast Cancer (CO44657)

A012301 LoTam Molecular Low-risk Early-Stage Breast Cancer

TROPION-Breast04 (Triple Negative Breast Cancer)

Publications, Grants & Awards

Grants (5)
Awards (2)
Academics Articles (15)
Conference Pages (9)
Book Sections (2)

A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician's choice chemo, for the treatment of participants with metastatic HER2-positive breast cancer

2025-2030Jazz Pharmaceuticals

A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer with Resist...

2024-2029Genentech, Inc.

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembroliz

2024-2029AstraZeneca Pharmaceuticals, LP

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre-and Postmenopausal Women and Men with Locally

2024-2028Sermonix Pharmaceuticals

CAMBRIA-1:ER+/HER2- Early Stage Breast Cancer being treated with Endocrine Therapy after Surgery

2024-2028AstraZeneca Pharmaceuticals, LP

DCI Centers, Cancer Types & Labs

Breast Cancer

Duke Center for Brain and Spine Metastasis

Offices & Contact

4101 Macon Pond
Raleigh, NC
27607